Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07235059 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
A Phase 1 study of Chronic Kidney Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
- 2
- Study locations
NCT07235059 is a Phase 1 study of Chronic Kidney Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 112 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07235059, a Phase 1 study of Chronic Kidney Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG OJR520
Study Locations (2)
Florida
- Quotient Sciences Sea View - Miami
Other
- Novartis Investigative Site - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-11-20 |
| Est. Completion | 2027-07-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07235059
The ClinicalTrials.gov registry entry for NCT07235059 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07235059 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Other.
Frequently Asked Questions
What is clinical trial NCT07235059 about?
NCT07235059 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease". The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
What is the current status of trial NCT07235059?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2025-11-20. Estimated completion is 2027-07-19.
What conditions does trial NCT07235059 study?
This clinical trial studies the following conditions: Chronic Kidney Disease.
What interventions are being tested in trial NCT07235059?
The interventions under investigation include: Placebo (OTHER), OJR520 (DRUG).
Who is sponsoring clinical trial NCT07235059?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07235059 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sympatholysis in Chronic Kidney Disease
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
RECRUITING · Phase 1
-
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
COMPLETED · Phase 1
-
A Trial of Doxycycline in Renal Disease
COMPLETED · Phase 1
-
A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
COMPLETED · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.